BDA and William Blair advise Ritedose on its sale to Novo Holdings

We are pleased to announce the sale of The Ritedose Corporation (“Ritedose”) by a consortium led by European-Asian fund AGIC Capital to Novo Holdings A/S. BDA Partners and William Blair acted as financial advisors to Ritedose on the sale.

Founded in 1995 and headquartered in Columbia, South Carolina, Ritedose is a leading sterile pharmaceutical manufacturer, specializing in the use of blow-fill-seal (“BFS”) technology. Ritedose provides outsourced manufacturing of ophthalmology drugs, respiratory drugs, and vaccines. In addition, Ritedose develops and markets its own portfolio of generic drugs and is an emerging player in the outsourced sterile compounding market focusing on medically necessary drugs that are in short supply. Ritedose’s customers range from small startups and large pharmaceutical companies to wholesalers, retail pharmacies and hospital systems. Today, the company employs over 400 people and is led by Chief Executive Officer Jody Chastain, who will continue to run the company under Novo Holdings’ ownership.

Andrew Huntley, Managing Partner and Global Head of Healthcare at BDA, said: “This noteworthy deal continues the run of the pharma manufacturing services sector attracting strong investor appetite globally, especially for companies with differentiated capabilities such as Ritedose. I’m proud that BDA and William Blair could use our sector expertise and experience of numerous transactions in pharma services to help deliver this outcome for Ritedose and its shareholders.”

Anthony Siu, Partner & Co-Head of Shanghai at BDA, commented: “We are pleased to have helped AGIC successfully exit its investment after partnering with Ritedose in its growth over the past few years. As well as pharma services and CDMO, BDA has a strong track record across all the sub-sectors of healthcare with private equity firms and corporates in Asia.”